PMID- 10100143
OWN - NLM
STAT- MEDLINE
DCOM- 19990525
LR  - 20190921
IS  - 0169-5002 (Print)
IS  - 0169-5002 (Linking)
VI  - 23
IP  - 1
DP  - 1999 Jan
TI  - Concurrent chemotherapy with hyperfractionated accelerated thoracic irradiation 
      in stage III non-small cell lung cancer.
PG  - 19-30
AB  - OBJECTIVES: We evaluated the effect of hyperfractionated accelerated radiotherapy 
      combined with low dose radiosensitisers followed by standard dose chemotherapy in 
      the treatment of unresectable stage III non small cell lung cancer (NSCLC). 
      METHODS: Forty-seven patients received thoracic radiotherapy (1.5 bid x 5 days x 
      4 weeks) in combination with low dose daily (3-6 mg/m2) cisplatin +/- weekly 
      vinblastine chemotherapy (step I), followed by three cycles of standard dose 
      chemotherapy alone consisting of cisplatin (75-80 mg/m2) and vinblastine (8-16 
      mg/m2) given at 3-4 week intervals (step II). RESULTS: The overall response rate 
      was 70% (21% CR). The progression free interval and the median survival duration 
      were 10.4 months and 17.3 months, respectively. The 3 year survival rate was 21%. 
      The site of first progression was local in 44%, distant in 41%, and simultaneous 
      in 15% of patients. Levels of esophageal toxicity were significant but acceptable 
      with the use of prophylactic therapy. Grade 3 or 4 esophageal toxicity was 
      observed in 28 and 19% of patients during step I and II of the study, 
      respectively. There were three deaths associated with esophageal toxicity. All 
      occurred prior to the implementation of the prophylactic therapy for esophagitis. 
      Acute pulmonary symptoms were reported in 25% of patients in step I, and 
      pulmonary fibrosis, primarily asymptomatic, was observed in 51% of patients. 
      Hematological toxicity was moderate. Two patients died of neutropenic 
      sepsis/pneumonia. CONCLUSION: Concurrent chemotherapy and hyperfractionated 
      accelerated radiotherapy followed by chemotherapy appears moderately effective in 
      controlling tumour growth as measured by response rates and survival estimates. 
      Toxicity is considerable but manageable and compatible with results from other 
      combined modality studies.
FAU - Lochrin, C
AU  - Lochrin C
AD  - Cancer Care Ontario, Ottawa Regional Cancer Centre, Ont, Canada.
FAU - Goss, G
AU  - Goss G
FAU - Stewart, D J
AU  - Stewart DJ
FAU - Cross, P
AU  - Cross P
FAU - Agboola, O
AU  - Agboola O
FAU - Dahrouge, S
AU  - Dahrouge S
FAU - Tomiak, E
AU  - Tomiak E
FAU - Evans, W K
AU  - Evans WK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Phytogenic/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/mortality/pathology/*radiotherapy
MH  - Cisplatin/administration & dosage
MH  - Combined Modality Therapy
MH  - Dose Fractionation, Radiation
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lung Neoplasms/drug therapy/mortality/pathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Vinblastine/administration & dosage
EDAT- 1999/04/01 00:00
MHDA- 1999/04/01 00:01
CRDT- 1999/04/01 00:00
PHST- 1999/04/01 00:00 [pubmed]
PHST- 1999/04/01 00:01 [medline]
PHST- 1999/04/01 00:00 [entrez]
AID - S0169500298000981 [pii]
AID - 10.1016/s0169-5002(98)00098-1 [doi]
PST - ppublish
SO  - Lung Cancer. 1999 Jan;23(1):19-30. doi: 10.1016/s0169-5002(98)00098-1.